Bristol Myers Squibb 4Q Revenues: $12.5 billion +1%  4Q Earnings: $1.1 billion (earnings were $72 million 4Q24) FY Revenues: $48.2 billion (flat) FY Earnings: $7.1 billion (loss of $8.9 billion FY24)  Comments:  Growth Portfolio revenues were $7.4 billion in the quarter, up 16% primarily driven by the immuno-oncology portfolio, Camzyos, Breyanzi and Reblozyl. Camzyos sales were $353 million, up 59%. Breyanzi sales were $392 million, up 49%. Reblozyl sales were ...